December 30, 2025 8:02am

Selling with home sales data and Fed minutes as December, Q4 and FY25 draws to an end in 2 sessions

As I have written; “It’s been a good clue to be reducing “some” exposures, exiting some also-rans or questionable data delays

News: Mesoblast (MESO +$0.60 or +3.16% to $19.56) re-finances its debt load, fully repaid its existing senior secured loan from Oaktree with a new 5-year facility provided by existing MESO shareholder and director Dr Gregory George

Pre-open Signals: 3 Positive, 1 Neutral and 1 Negative

Never leave retail investor uninformed … I say what others won’t, so you can do what others can’t!

 

 

Looking forward to 2026, investors are likely to focus on whether these high-performing biotech stocks can sustain their momentum through clinical execution, regulatory milestones, commercialization progress, and potential strategic transactions.

RMi Research Note: Harvard Apparatus GT (OTCQB: HRGN): I reiterate WHO is pumping the volume and share pricing? … https://www.regmedinvestors.com/articles/13812   

 

Tuesday (12/30): The pre-open Dow futures are DOWN -0.01% or (-7 points), the S&P futures are DOWN -0.04% or (-3 points) and the Nasdaq futures are DOWN -0.05% or (-12 points)

  • Stock futures trading are crawling negative and flip-flopping on Tuesday, 12/30,
  • European markets are mixed,
  • Asia Pacific markets fell,

Economic Data: Home price data due at 9 a.m. ET. The Fed’s December meeting minutes are also expected, slated for a 2 p.m. release.

 

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

  • Monday: The Dow closed DOWN -249.04 points or -0.51%, the S&P closed DOWN -24.20 points or -0.35% while the Nasdaq closed DOWN -118.748 points or -0.50%
  • Friday: The Dow closed DOWN -20.19 points or -0.04%, the S&P closed DOWN -2.11 points or -0.03% while the Nasdaq closed DOWN -20.2 points or -0.09%
  • Last week: The S&P 500 was up +1.4%, the Dow +1% and the Nasdaq was also up +0.1%
  • The previous week: The S&P 500 was up +0.1%, the Dow slipped -0.7% and the Nasdaq was up +0.5%.
  • November ended: the S&P 500 and Dow were slightly higher, as the Nasdaq fell 2%,

 

Q4 – December, 1 holiday, 8 positive and 12 negative closes

  • November, 1 holiday, 8 positive and 11 negative sessions
  • October, 1 neutral, 10 positive and 12 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Capricor Therapeutics (CAPR) closed up +$0.35 after Friday’s +$0.01 (having been down -$0.27) after Wednesday’s -$0.57) … with a neutral pre-open - SELL

  • I am STICKING to my CONVICTION that CAPR is overbought and whose valuation is disconnected from fundamentals.
  • Doubts still abound re: regulatory fragility and marginal HOPE-3 results and valuation concerns remain a key hang-up!
  • CAPR remains a structurally challenged, chronically unprofitable company whose valuation is disconnected from fundamentals.
  • It has begun; timing will be everything!
  • The higher CAPR rises, the steeper the fall!

CRISPR Therapeutics (CRSP) closed down -$1.11 after Friday’s dropped -$1.63 with a positive +$0.28 or +0.52% pre-open

  • Cathie Wood’s ARK Investment bought into CRSP and makes-up roughly 3.81% of assets; ARK loaded up on over 76,800 shares of CRISPR in just three trading days.

BioNTech (BNTX) closed up +$0.68 after Friday’s down -$0.51 with a positive +$0.36 or +0.38% pre-open

Ionis Pharmaceuticals (IONS) closed up +$0.04 after Friday’s -$0.72 with a negative -$0.04 or -0.05% pre-open

Mesoblast (MESO) closed down -$0.54 re-finances its debt load, with a positive +$0.60 or +3.16% pre-open  

 

The BOTTOM LINE: Welcome to my world of defining the “grey’ in our universe!

  • Stocks are entering the final stretch of 2025 trading,
  • With a downside end-of-month and year rotation and rebalance, In the last of December and 2025, it means investors have to be careful of slippage targets.

Streaking across sessions … however, it’s about ending 2025 without … considering what headwinds are about to be faced in the beginning months of 2026.

 

Investors are hoping for continued momentum, as they gauge the prospects for a Santa Claus rally.

  • after a surprise drop in inflation and lukewarm labor market data left betting on possible 2026 interest-rate cuts

All 3 major indexes will enter the final 7 trading sessions of 2025 within 3% of their record highs.

  • In the week ahead, those investors still around during the holidays will turn their attention to the prospects of a “Santa Claus rally,” while a few pieces of economic data out on Tuesday will clean up some of the lagging data delayed as a result of the government shutdown.
  • Tuesday morning’s read on consumer confidence from the Conference Board should be the key focus, with one of 2025’s defining narratives centering on the K-shaped economy that has emerged among American shoppers.

 

5th and last week of December, Q4 and FY25

  • Monday closed negative with 12 positive, 24 negative and 4 flats

4th and final and short week of December to include Christmas holiday

  • Friday closed negative with 11 positive, 28 negative and 1 flat
  • Thursday was a holiday
  • Wednesday closed positive with 31 positive, 5 negative and 4 flats - not published
  • Tuesday closed negative with 14 positive, 24 negative and 2 flats
  • Monday: Monday closed positive with 30 positive, 8 negative and 2 flats

 

NOT a ... doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.